Background: Viral hepatitis with various forms of acute and chronic liver disease as potential and ultimately fatal sequelae presents a public health problem worldwide. Methods: Recent published reports on the global epidemiology and prophylaxis of viral hepatitis were reviewed. Results: With the advances in novel technologies, eight distinct types of hepatitis virus have been described: Hepatitis A, B, C, D, E, G, TT and SEN viruses. Hepatitis A and E viruses are transmitted by the fecal-oral route and do not induce a chronic carrier state. Due to major changes in epidemiology of hepatitis A virus their significance is more pronounced in areas of intermediate endemicity. Since the available hepatitis A vaccine is rather expensive, cost-benefit studies should be performed with emphasis on the area under consideration or specialized vulnerable groups. Parenterally transmitted hepatitis B and C viruses are major causes of chronic liver disease, including cirrhosis, hepatocellular carcinoma and end-stage liver failure. Hepatitis D virus is unable to replicate on its own, it requires an established hepatitis B virus infection to be able to replicate. Since its introduction, hepatitis B vaccine has been widely used leading to a significant decrease in HBV infection in countries with universal vaccination. Hepatitis G and TT viruses have been characterized within the latter part of the past decade but their significance as to the causation of human liver disease has yet to be elucidated. Likewise, the precise impact of the most recently described SEN virus isolated from patients with post-transfusion hepatitis awaits further studies. Conclusions: In the course of this review, we present the situation and focus on research activities emphasizing epidemiology and prevention of the various forms of viral hepatitis.
INTRODUCTION
Viral hepatitis has remained a major public health problem worldwide. With the advance in technologies, eight distinct types of hepatitis viruses have been described so far: Hepatitis A, B, C, D, E, G, TT and SEN viruses. In this article, we review the present situation on epidemiology and prophylaxis of various forms of viral hepatitis in the global perspective.
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Y Poovorawan et al. those in older children and adults are usually symptomatic, with jaundice occurring in more than 70% of the patients. Improvement in personal hygiene and environmental sanitation have led to a decline in natural immunity against the virus. This has lead to an increasing number of susceptible adults.
Epidemiology
Seroepidemiological studies of HAV were undertaken in various parts of the world. The following data are grouped by region.
In the past, Latin America was considered an area of high endemicity for hepatitis A virus (HAV) infection, with most people infected in early childhood. A seroepidemiological study was recently undertaken in six countries (Argentina, Brazil, Chile, Dominican Republic, the Republic of Mexico, and Venezuela). 1 The highest anti-HAV seroprevalence rates were found in Mexico and the Dominican Republic, with the remaining four countries' studies all yielding very similar results. Analysis of the different age groups has shown that at the age of 6-10 years, 30% of children in Chile and 54-55% in Brazil, Venezuela and Argentina had been infected, compared with almost 70% in Mexico and 80% in the Dominican Republic. At the age of 11-15 years, nearly 90% in Mexico and 91% in the Dominican Republic had been infected, compared with 54% in Argentina, 62% in Venezuela, 60% in Brazil and 70% in Chile. By the age of 31-40 years, over 80% of the populations in all six countries had been exposed to HAV. The greatest risk factors for HAV infection in Latin America were related to water and food. The results show that there has been a shift from high to medium endemicity of HAV infection throughout Latin America. This change may increase the potential for outbreaks to occur in these areas of the world.
The prevalence of HAV infection varies among countries in Asia. 2 The countries with low endemicity include Japan, Taiwan, Singapore and Hong Kong, whereas those with moderate endemicity include Indonesia,Thailand, Sri Lanka and Malaysia. Countries with high endemicity for HAV infection include India, China, Nepal, Bangladesh, Pakistan, Myanmar and the Philippines. A review of the epidemiology of HAV infection over the last 20 years has shown shifting patterns in the prevalence of antibodies to HAV throughout South-East Asia and China from high to moderate and from moderate to low endemicity. 3 Variations in prevalence rates also occur in different regions of the same country, for example in rural compared to urban areas, or populations of low compared to high socioeconomic status. These variations reflect the impact of living standards and environmental hygiene on the prevalence of HAV infection. 4 In the late 1970s and early 1980s, 85-95% of the population in developing countries, like the Philippines, Korea, China and Thailand, were anti-HAV-positive by the age of 10-15 years, compared with only about 50% in Malaysia and Singapore.
There has been a significant decrease of seroprevalence among school children in Thailand within the last 10 years. In the year 1999, most children and adolescents have been susceptible to the disease. 5 Thus, exposure to HAV infection had shifted from childhood to young adulthood. In Singapore, there has been a dramatic decrease in HAV infection. In 1975, the entire population over 30 years of age had anti-HAV antibodies and in 1985, this proportion had declined to approximately 50%. 6 By 1991, less than 50% of the 40-year-olds had anti-HAV antibodies 7 and almost none of the 10-year-olds had naturally acquired antibodies. In southern Taiwan the seroprevalence of HAV in subjects aged 0.3-63 years was shown to be 15%, which was lower than that in 1992. 8 Finally, in Hong Kong, a study of HAV seroprevalence in secondary school children showed that the overall prevalence is 7%. The seroprevalence for age group 11-20 years had fallen compared with 44.8% in 1978, 17.1% in 1987 and 11.2% in 1989. 9 These data strongly support the shift of HAV epidemiology in South-East Asia and China to resemble that in other parts of the world.
There is a shortage of data on endemicity of HAV infections in Africa and the Middle East. Africa has generally been considered a region of high endemicity for HAV infection, 10 with South Africa as the only exception. A study published in 1994 has shown almost 100% of black adults in South Africa under the age of 20 years were positive for antibodies to HAV, whereas only 30-40% of white adults were anti-HAV-positive by the age of 20 years, experiencing an increase to about 60% by the age of 40-49 years. 10 From data in 1995-1996, Qatar and the United Arab Emirates were found to be areas of intermediate endemicity with approximately 60% of the population below the age of 20 years anti-HAV-positive. 11 Seroprevalence of anti-HAV antibodies in the Israeli population depends on ethnic origin, being highest in those of North African origin and lowest in those of Western origin 12 Recent seroprevalence studies indicate that by age 18 years only approximately 30-40% of the Jewish population have anti-HAV antibodies. 13 In Saudi Arabia, previous studies generally have shown very high prevalence rates, with most people becoming infected in early childhood. Between 1989 and 1995, however, there has been a significant decline in the seroprevalence of HAV-antibodies in children up to 12 years of age throughout the country except for one region bordering on Yemen. 11 These data indicate that the pattern of endemicity of HAV infection is shifting in Saudi Arabia, and probably in several other countries in the Middle East, as well.
In Australia, 41.1% of 3043 serum samples obtained from around the country in 1998 were found seropositive for HAV. Seroprevalence was significantly associated with increasing age. These data show that about half the Australian population has not been exposed to HAV and is therefore susceptible to infection. 14 The countries in Eastern Europe can be divided into two groups based on HAV infection morbidity. 15 One group comprises Slovakia, the Czech Republic, Poland and Bulgaria, which have been intermediate endemicity areas for many years, whereas Lithuania, Latvia, Russia and Romania are now undergoing a period of transition towards intermediate endemicity.
Statistical databases of morbidity rates for hepatitis A in the mid-1990s for nine Eastern European countries revealed that morbidity was highest in the Ukraine, lower in Lithuania, Latvia, Russia, Romania, Bulgaria and Poland, and lowest in the Czech Republic and Slovakia. 16 The USA and Scandinavian countries are considered an area of low endemicity for HAV. It has been estimated by the Centers for Disease Control (CDC) that there are approximately 180 000 HAV infections in the USA annually, half of which are symptomatic. 17 A large proportion of HAV infection in the USA occurs in regions or populations with endemic hepatitis A, such as Native American reservations, 18 and Native Alaskan villages. 19 The native Swedish population has a low natural exposure to HAV, which has not changed over the past decades. 20 The prevalence gradually declined from 6% in those born in the 1940s to 2% in those born after 1950.
Hepatitis A prophylaxis, vaccine and cost effectiveness
Preventive measures for HAV infection include improvement of personal hygiene, health education, disease surveillance and outbreak control. Immunoprophylaxis with immune serum globulin and vaccine constitutes another approach. Even though inactivated hepatitis A vaccine has proven highly immunogenic and efficacious, 21 one important factor that has to be considered in developing vaccination strategies for any given area is cost-effectiveness. There have been several studies in different parts of the world focusing on this issue. A recent study in Germany 22 analyzed the epidemiological and economic impact of combined hepatitis A and hepatitis B vaccination employing three vaccination strategies: vaccination of all children between one and 15 years of age, vaccination of all children aged 11-15 years, and no vaccination strategy projected over a period of 10 years. The study has shown the strategy of vaccinating 11-15-year-olds to be the most cost-effective, but it would leave a large percentage of the population at high risk of HAV infection. Applying an initially more expensive combined hepatitis A and B vaccine may be more beneficial in terms of its epidemiological impact. In Israel, cost-benefit analysis of a nationwide infant immunization program against hepatitis A in an area of intermediate endemicity has shown the policy both medically and economically justifiable with health service, resource and societal benefit-cost ratios of 1.80 : 1, 2.13 : 1 and 2.54 : 1, respectively. 23 A study conducted among healthcare workers and the general population at risk in Ireland has shown the most cost-effective strategy related to target group immunity. Where HAV immunity amounts to 45% or less, vaccination is the strategy of choice and when immunity exceeds 45%, screening should be performed before vaccination. 24 Analysis of cost-effectiveness of various vaccination strategies in healthy adults in the USA has proven the 'vaccination' strategy to be cost-effective when one dose of vaccine costs $7 or less (baseline $57). 25 Under baseline conditions, neither the screening nor vaccination strategies are considered cost-effective according to current standards. Cost-effectiveness of HAV vaccination in the general population in Thailand has recently been investigated leading to a similar conclusion. 26 Under the current circumstances in Thailand, the benefit of vaccination to the general population aged between three and 40 years old would not justify the expense incurred. For the benefits to outweigh the cost in the 3-11-year age group, the cost of vaccine has to be approximately $5.5 per single dose.
The Advisory Committee on Immunization Practices (ACIP) in 1996 recommended that children living in communities with the highest rates of infection and disease should be vaccinated. 27 In the most recent publication in 1999, ACIP recommends routine vaccination for children in states, counties and communities where the annual attack rate equals or exceeds 20 cases per 100 000 population, and consideration of routine vaccination for children in states, counties and communities where the attack rate is between 10 and 20 cases per 100 000 population 17 Vaccination should be considered for special groups of persons that are at a high risk of HAV infection. These include persons from areas of low endemicity travelling to or working in an area of high or intermediate endemicity, homosexual men, intravenous drug addicts, persons with an occupational risk for infection, such as those who work with HAV-infected primates or with HAV in a research laboratory setting, and finally, persons with clotting-factor disorders. Persons with chronic liver disease have a high mortality rate when infected with HAV; 28 therefore, susceptible persons who have chronic liver disease should be vaccinated. Vaccination should also be considered for food handlers because of their potential to spread the disease if they are infected.
HEPATITIS B
Hepatitis B virus (HBV) is a member of the hepadna virus family. HBV infection remains a major contributor to the global disease burden. There are at least 350 million carriers of HBV worldwide. 29 At least one million individuals chronically infected with HBV die each year from chronic liver disease, including cirrhosis and liver cancer. 30 From a global perspective, HBV infection is as important as any other vaccine-preventable disease. The global prevalence of chronic HBV infection varies from high (≥ 8%) in Africa, Asia and the Western Pacific to intermediate (2-7%) in Southern and Eastern Europe, and low (< 2%) in Western Europe, North America and Australia. However, due to the success of HB vaccination programs, many countries are in transition from high or intermediate endemicity to intermediate or low endemicity, respectively. 31 The Asian and the Western Pacific regions account for approximately three quarters of chronic HBV carriers. 32 Countries with numerous immigrant ethnic groups from various endemic populations have mixed endemicity. In highly endemicity populations, most infections occur during birth (perinatally, vertical transmission) or during childhood (horizontally). Contrasting that, in populations with low endemicity, HBV is transmitted sexually or parenterally in the majority of cases.
Hepatitis B virus infecting humans are classified into seven genotypes differing from each other by nucleotide sequence distances of approximately 10-15%. 33, 34 Genotypes A and D have global distributions genotypes B and C are found predominantly in East and South-East Asia. Genotype E prevails in West Africa. The most divergent genotype F is found exclusively among indigenous peoples in Central and South America. 35 Genotype G, found in the USA and France, exhibits some unique molecular structures. 34 Hepatitis B virus is transmitted by percutaneous and mucous membrane exposure to blood and other infectious body fluids. Modes of HBV transmission include intravenous drug use, sexual or household contact with an infected person, perinatal transmission and nosocomial exposure. 36 Nosocomial transmission accounts for a substantial disease burden in countries with inadequate infection control practices, including reuse of contaminated medical or dental equipment, failure to use appropriate disinfection and sterilization practices for equipment and environmental surfaces, and improper use of multidose medication vials. Blood transfusion can also be a major source of HBV transmission in countries where the blood supply is not screened for HBsAg.
Comprehensive HBV prevention strategies should include prevention of perinatal and nosocomial HBV transmissions, as well as hepatitis B vaccination at critical ages to interrupt transmission. The choice of specific strategies for a particular country depends on country-specific factors, including the epidemiology of HBV infection.
Prevention of perinatal HBV transmission
Two different strategies can be applied to prevent this mode of transmission. First, prevention can be integrated as a component of the routine infant vaccination beginning soon after birth with the 3-dose vaccine series which are completed by six months of age. Second, all pregnant women are screened for HBsAg and immunoprophylaxis provided to infants of HBsAg-positive mothers.
The major factor that influences the efficacy of postexposure prophylaxis is the timing of the first dose of vaccine in relation to birth; efficacy is optimal when the vaccine is administered within 24 h after birth. 30 
Prevention of nosocomial HBV transmission
Measures required to prevent HBV transmission from patient to health-care provider include implementing standard barrier precautions, such as gloves, gowns and protective eyewear to prevent exposure to blood; preventing needle-stick and other sharp instrument injuries (e.g. avoid recapping needles, use impervious containers for disposal of needles); and using appropriate disinfection practices. 37 All health-care providers who are exposed to blood should receive pre-exposure vaccination. Measures required to prevent transmission from patient to patient include screening of blood supplies for HBsAg; using sterile equipment for injections as well as for surgical and dental procedures; preparing medications in an area separate from that used for processing blood specimens; and avoiding the use of multidose medication vials.
Hepatitis B vaccination at critical ages to interrupt transmission
Chronic liver disease and liver cancer develop in persons chronically infected with HBV. These persons also serve as the major reservoir for transmission of new infections. In highly endemic areas, routine infant vaccination is the primary essential strategy to prevent HBV transmission in children in whom a high proportion of chronic infections may occur. In countries with intermediate and low HBV endemicity, vaccination strategies for older children, adolescents and adults may be desirable because most infections occur among these populations.
Coverage of hepatitis B vaccine

Oceania
Infant vaccination coverage rates ranged from 45% in Papua New Guinea to 100% in Niue. 38, 39 The coverage figures of most of the countries in this region exceeded 80%. New Zealand has a universal HB immunization programme which covered 87% of the infant population. 40 Nevertheless, Australia has not yet fully implemented universal infant and preadolescent vaccination.
East and South-East Asia
China provided HB vaccine to 87% and 55-76% of infants in urban and rural areas, respectively. 41 Taiwan has implemented universal HB vaccination for infants since 1986 with a coverage rate recently amounting to 84-94%. The vaccine coverage figures in infants of the Philippines, Indonesia, Vietnam, the Republic of Korea, Malaysia, Thailand, Macao, Singapore, and Brunei Darussalam were 34%, 62%, 69%, 86%, 91%, 92%, 92%, 96%, and 100%, respectively. 38, 42 In Japan, infants of HB-infected mothers are vaccinated. 32, 43 Other countries are in the process of developing the immunization program.
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South and Central Asia
Although populations in this region have intermediate to high endemicity, most countries cannot afford the vaccine. Bhutan, Maldives, Kazakhstan and Mongolia attained vaccination coverage rates of 45%, 45%, 49% and 91%, respectively. 38 
Middle East and North Africa
Most countries in this region have HB immunization programs with high infant coverage rates ranging from 65% to 99%.
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Southern and Eastern Europe
The infant vaccination coverage rates ranged from 9% in Latvia to 100% in Romania. 38, [46] [47] [48] Some countries also vaccinated schoolchildren and adolescents. [46] [47] [48] 
Northern Europe
Due to low endemic rates, most countries vaccinated only high-risk groups and infants of HBV carriers.
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Sub-Saharan Africa
The infant HB vaccine coverage rates ranged from 69% in Botswana to 96% in the Seychelles. Burkina Faso, Cote d'Ivoire, Gabon, Mali, Tanzania and Zambia are planning HB immunization programmes. 38 
The Caribbean, Central and South America
The infant HB vaccine coverage rates have ranged from 13% in Brazil to 100% in Saint Kitts and Nevis. 38, 42, 45 Chile, Dominica, Guyana, Honduras, Peru and Venezuela have provided vaccine to high-risk populations, such as medical personnel or certain Native American groups.
North America
Universal HB immunization in children at or below the age of 18 years has been recommended in the United States. 40 Most provinces in Canada have provided school-based universal immunization of adolescents, whereas only three provinces have provided universal infant immunization programs.
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Long-term protection of hepatitis B vaccine
A safe and effective vaccine to prevent HBV has been available for approximately two decades. Protection against clinically significant breakthrough HBV infection and chronic carriage is expected to last longer than detectable antibody after HB immunization. It is clear that immune memory remains intact for at least 10 years following immunization. 54, 55 Follow-up studies for up to 10-15 years have shown high safety and continuing immunity. 56, 57 The European Consensus Group on Hepatitis B Immunity has concluded that there are no data to support the need for booster doses in immunocompetent individuals who have responded to a three-dose primary course. 58 Unnecessary routine booster doses incur enormous expense both in developed and, more importantly, in developing countries.
Impact of the universal hepatitis B immunization program
By 1999, 108 out of 211 countries had implemented universal infant or adolescent immunization programs against hepatitis B.
40 Selective HB immunization provided only to high-risk groups in countries of low endemicity could not substantially reduce HB transmission. 29 Universal immunization remains the only strategy that will reduce the long-term disease burden of HBV, such as hepatocellular carcinoma. 59, 60 Addition of HBV vaccine to the national immunization program is one of the most cost-effective medical interventions. The factors affecting a government's decision regarding HB immunization are: cost, this is the most important factor; experiences with HB immunization strategies; strength of the current immunization program; and perceptions of vaccine safety as well as immunogenicity.
Routine childhood HB vaccination programs reduced the prevalence of chronic HBV infection to < 1% and < 2% in areas with low and high rates of perinatal HBV transmission, respectively. 44, 61 These interventions also led to a reduction in acute hepatitis cases, and among the middle-aged population a reduced incidence of liver cancer. 56, 59, 60, 62 Hepatitis B vaccine contains thimerosal, a commonly used preservative that contains mercury and thus in July 1999, The American Academy of Pediatrics (AAP) and the Public Health Service (PHS) recommended suspending HB vaccination at birth except for mothers with positive or unknown HBsAg status. Two months later, the Centers for Disease Control and Prevention (CDC) recommended the resumption of HB vaccination with a new thimerosal-free HBV vaccine. One year subsequent to this policy change, the number of hospital nurseries routinely offering HBV immunization decreased. 63 Altering recommendations, especially if implemented without timely communication and education for the health-care providers, may result in misinterpretation and unanticipated changes in vaccination practice. 64 However, thimerosal is a very effective preservative and has been widely used in some vaccines and other products since the 1930s.
Combined hepatitis B-DTP vaccine
Combined vaccines, such as DTP-HB, offer the benefits of increased compliance, time and cost savings for medical personnel administering the injections and reduced work/school disruption. These vaccines have proven highly immunogenic and hence, provide longterm protection against these antigens.
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HEPATITIS C
Hepatitis C virus (HCV) is an RNA virus belonging to the family of flaviviridae with the most closely related human viruses being yellow fever, dengue and Japanese B encephalitis viruses. S160 Y Poovorawan et al.
An estimated 3% of the global population, or about 170 million individuals, have been infected with HCV. 66 The prevalence rates estimated by WHO in 1999 were 1.03%, 1.7%, 2.15%, 3.9%, 4.6% and 5.3% in Europe, North and South America, South-East Asia, the Western Pacific, Eastern Mediterranean and Africa, respectively. 67 Egypt had large-scale HCV infection with the prevalence ranging from 6% to 28% due to the use of unsterile injection equipment for bilharzia treatment in the 1950s-1960s. 68 Most HCV-infected individuals are unaware of their clinical status and hence, the prevalence of infection may be under-reported. About 85% and 70% of infected persons become chronically infected and develop chronic hepatitis, cirrhosis and hepatocellular carcinoma, respectively. An estimated 5-10% of chronically infected persons may eventually die from either cirrhosis or liver cancer. 30 Hepatitis C virus can be grouped into at least six genotypes corresponding to the main branches in the phylogenetic tree. 69 In the USA and Western Europe, genotypes 1a and 1b are most common, followed by types 2 and 3. 70 Genotype 4a is found at high frequency in the Middle East, particularly in Egypt. 68 In Africa, infection with genotypes 2, 4 and 5 is most predominant, [70] [71] [72] [73] whereas genotypes 1, 3 and 6 prevail in SouthEast Asia. 33 Hepatitis C virus is transmitted by direct percutaneous exposure to infected blood, such as via blood transfusion from infectious donors, sharing of contaminated equipment among intravenous drug addicts and needlestick injuries among health-care workers. Kane et al. estimated that approximately 2.3-4.7 million HCV infections might occur annually due to improperly sterilized injection equipment. 36 HCV can also be transmitted from infected women to their infants, especially from HIV-1 coinfected mothers and by sexual or household contact with an infected person. [74] [75] [76] Prevention of hepatitis C is problematic because a vaccine to prevent HCV infection is not expected to be developed in the foreseeable future and immune globulin is not effective for postexposure prophylaxis. There are several obstacles in developing an HCV vaccine. 77 First, HCV exhibits high sequence diversity among strains within and between geographic areas. Second, HCV isolates with rather divergent sequences in certain regions of the viral genome (quasispecies) are present and mutations occur frequently during the course of infection. The amino acid changes observed in the hypervariable region 1 (HVR1) located in the hepatitis C envelope protein E2, are postulated to facilitate escape from neutralizing antibodies. Third, immunologic correlates associated with disease progression or protection are not well defined. Fourth, there is no reliable tissue culture system for testing neutralizing antibodies and expanding or passaging HCV. Last but not least, the only reliable model for HCV infection is the chimpanzee, which is costly, difficult to study and its infection may not mirror that of humans.
The greatest impact on HCV disease burden is achieved by primary prevention to reduce or eliminate the risk of transmission via nosocomial exposures (e.g. transfusion of blood and blood products, use of unsterile medical and dental equipment, unintentional needlesticks) and high-risk practices (e.g. unsafe injection practices, intravenous drug use, promiscuous lifestyle without taking precautions).
Measures to prevent nosocomial HCV transmission are similar to those recommended for HBV. Exclusion of donors at increased risk of infection or seropositive for HCV can prevent transmission via blood and blood products. Transmission of HCV associated with high-risk practices can be prevented by identifying and counselling persons indulging in these practices. Community-based services should facilitate prevention and reduction of high-risk behaviors. Programs to increase access to sterile syringes can enhance safer injection practices among injecting drug users.
Due to high rates of progression to chronic infection, lack of both efficient treatment and effective means of prevention means that HCV infection will undoubtedly remain a clinical challenge throughout the world.
HEPATITIS D
Hepatitis D virus (HDV) is a virusoid that requires the surface coat of HBV (HBsAg) in order to be infectious. Acute HDV/HBV coinfection may be associated with a higher rate of fulminant hepatitis. Superinfection with HDV in individuals with chronic HBV infection can lead to both acute and more progressive liver diseases. The prevalence of HDV infection is decreasing due to several factors, such as decline in the prevalence of chronic HBsAg carriers, introduction of disposable needles and syringes together with improvement of socio-economic conditions. Despite its declining prevalence, HDV still accounts for about 5% of HBV carriers or approximately 15 million individuals. 78 Most of these individuals are proceeding towards severe liver damage and hence, have a sizeable impact on worldwide morbidity and mortality. Hepatitis D virus continues to be a worldwide problem particularly among intravenous drug users. [79] [80] [81] [82] Three distinct genotypes of HDV have been classified. Genotype 1 represents the predominant one in most areas of the world. 83, 84 Genotype 2 is found in Japan and Taiwan. 85 Genotype 3 has been isolated in Peru, Venezuela and Columbia. 86 Hepatitis D virus infection in Thailand is found only in intravenous drug users who are HBV carriers and this trend is on the decrease. The only genotype encountered in this region thus far is genotype 1.
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Prophylaxis against HDV infection by HBV vaccination can only protect HDV-susceptible individuals from coinfection. Despite the present incapacity to prevent super-infection of HBV carriers, universal immunization against HBV and thus annihilation of the helper for survival and entry to the liver represents the only realistic approach to HDV prophylaxis. Eventually, this might lead to worldwide eradication of HDV and hence, diminish both acute and more progressive liver diseases.
HEPATITIS E
Hepatitis E (HEV) has previously been known as enterically transmitted non-A, non-B hepatitis. It is a nonen-veloped RNA virus classified in the family caliciviridae, genus Calicivirus based on its structural and physicochemical properties. Hepatitis E infection is endemic in South and Central Asia. Several outbreaks of hepatitis E have been observed in the Middle East, in northern and western parts of Africa and in Mexico. 88 Hepatitis E outbreaks are usually large, affecting several hundred to several thousand persons, and vary from short-lived, single-peaked outbreaks to prolonged, multimodal epidemics. During these outbreaks, overall attack rates range from 1-15%, being higher among adults (3-30%) than children (0.2-10%). The outbreaks are characterized by a particularly high attack rate and mortality (up to 25%) among pregnant women. 89, 90 The fecal-oral route is the predominant mode of transmission of epidemic HEV infection. Unlike HAV, which is also transmitted by the fecal-oral route, personto-person transmission of HEV appears to be distinctly uncommon during hepatitis E outbreaks. 91 Secondary attack rates among household members of hepatitis E cases are only 0.7-2.2%; in contrast, 50-75% of susceptible household contacts of hepatitis A cases are known to become infected. 92 The underlying causes of these differences in transmission patterns of HAV and HEV are presently unclear but may relate to differences in viral titres in stools of infected persons, number of viral particles required to cause disease, or viability of either virus in the environment. Environmental reservoirs of HEV in endemic areas may be responsible for recurrent epidemics.The potential reservoir of HEV during interepidemic periods in endemic areas may persist in the form of serial transmission among susceptible individuals who have sporadic or subclinical hepatitis E.Various data suggest that hepatitis E may be a zoonotic disease. Hepatitis E virus-RNA has been detected in the feces of domestic swine in Nepal 93 and anti-HEV antibodies have been detected in the sera of pigs, rats, chickens in endemic areas. 94 In addition, a US isolate of human HEV and swine HEV have been shown to be phylogenetically related. 95 In recent experimental studies, the US strain of human HEV has been shown to be infectious to specific pathogen free pigs. Moreover swine HEV has been transmitted to primates. 96 The prevalence of anti-HEV in healthy subjects has been studied in various populations worldwide. [97] [98] [99] [100] [101] In endemic areas of Asia and Africa, the prevalence rates among healthy populations are much higher than in nonendemic areas. In most endemic areas, anti-HEV has been detected in as many as 5% of children below the age of 10 years and this ratio increases to 10-40% among adults above the age of 25 years. These findings suggest that HEV infection, unlike that of other enterically transmitted agents, is infrequent among young children in developing countries.
Hepatitis E virus prevention
Preventing hepatitis E in endemic areas depends primarily on providing clean drinking water and proper sanitation. Boiling water before consumption appears to reduce the risk of acute hepatitis E; 102 however, no data are available regarding the efficacy of water chlorination. Isolation of affected persons is not indicated as person-to-person transmission is uncommon. 91 The protective role of anti-HEV antibodies in humans requires further study. No reduction in disease rates could be shown in pre or postexposure prophylaxis studies among recipients of immunoglobulin preparations manufactured in hepatitis E-endemic areas. 103, 104 In a recent study, administration of immune serum globulin to pregnant women during an outbreak has been shown to reduce the total number of de novo HEV infections, although the number of clinical cases has remained unchanged. 105 Thus, further research is required to elucidate the role of immune serum globulin in HEV prevention.There have been ongoing experiments in HEV vaccine development using recombinant protein and complementary DNA corresponding to HEV capsid protein which demonstrated that the vaccines can induce the development of anti-HEV. 106, 107 Further studies will be necessary to evaluate the experimental HEV vaccines.
HEPATITIS G, GBV-C
In 1995, two groups independently isolated a bloodborne virus from human serum applying the techniques of subtractive polymerase chain reaction (PCR) and reverse transcription (RT) PCR, respectively. The agent was found associated with post-transfusion hepatitis and subsequently termed GBV-C and/or HGV. [108] [109] [110] Also, as a blood-borne virus, HGV is mainly prevalent among members of high-risk groups, for example recipients of blood and blood products, 111, 112 hemodialysis patients, 113 intravenous drug users 114, 115 and individuals with impaired immune response, be it due to HIV infection 116 or immunosuppressive drug regimens. 117 HGV is usually found as a coinfection with other hepatotropic viruses. 118, 119 The virus can be transmitted parenterally 111, 115 vertically 120 or sexually, 121, 122 and after a prolonged asymptomatic course is usually eliminated by the patient's immune response. 123 Accordingly, although detected at high prevalence among the respective patients, the virus probably rather acts as an innocent bystander. Thus, as of now, there has been no unambiguous evidence as to GBV-C/HGV's role as a causative agent of acute or chronic liver disease and, with the exception of a few contradictory reports, the infections range from totally asymptomatic to mild. Hence, screening blood donors for the presence of HGV does not appear necessary.
TT VIRUS
In 1997, the last link in the chain of novel hepatitis viruses was identified by representational difference analysis (RDA) 124 as a single-stranded DNA clone of 500 nucleotides originating from the serum of a patient with post-transfusion hepatitis of unknown etiology. 125 This virus was named after the patient's initials, hepatitis TT virus, or TTV. Hepatitis TT can be found at high prevalence among healthy populations and among chronic liver disease patients. [126] [127] [128] [129] [130] [131] [132] Apart from humans,TTV can be detected in non-human primates. [133] [134] [135] The virus can be transmitted both parenterally 136 and orally (virus can be detected in fecal specimens). 137 The prevalence of TTV infection among blood donors and healthy populations in different countries is extremely high. [138] [139] [140] Due to the agent's high prevalence in healthy individuals and in chronic liver disease patients, no significant differences regarding demographic data, source of infection, biochemical abnormality or severity of liver histology have been found between TTV infected and non-infected chronic liver disease patients. 131 Neither does TTV cause posthepatitis aplastic anemia. 141 The pattern of infection with TTV appears to resemble that observed with GBV-C/HGV, the similarities even extending to the question of immune clearance, which appears to epitomize a certain impediment to individuals with impaired immune function. However, due to the high prevalence of TTV on a worldwide scale, along with its apparent lack of pathogenicity, 142 further studies will be required aimed at unequivocally establishing its contribution to the pathology inherent in liver disease.
SEN VIRUS
Researchers in Italy have recently discovered a potential hepatitis virus in the blood of immunosuppressed patients. Subsequently, eight different isolates belonging to a new group of single-stranded DNA viruses (SENV) distantly related to the TT virus family were identified, some of them associated with posttransfusion hepatitis. 143 Phylogenetic analysis using TTV-like minivirus as an outgroup and comparing 8 SENV isolates, 6 prototype TTV isolates and 7 TTV variants revealed four distinct clusters separated by a bootstrap value of 100%. The taxonomic classification thus obtained suggests these circular single-stranded DNA viruses to probably have evolved from a common ancestor. However, the clinical data are premature and in need of further investigation.
